Insider Selling: Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Sells $225,600.00 in Stock

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Dennis Helling sold 5,000 shares of Tabula Rasa HealthCare stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $45.12, for a total value of $225,600.00. Following the completion of the transaction, the director now owns 17,847 shares in the company, valued at $805,256.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Dennis Helling also recently made the following trade(s):

  • On Friday, January 17th, Dennis Helling sold 5,000 shares of Tabula Rasa HealthCare stock. The stock was sold at an average price of $51.27, for a total value of $256,350.00.

Tabula Rasa HealthCare stock opened at $53.05 on Friday. Tabula Rasa HealthCare Inc has a 52 week low of $33.04 and a 52 week high of $69.72. The company has a debt-to-equity ratio of 1.33, a quick ratio of 2.27 and a current ratio of 2.36. The firm has a market capitalization of $1.14 billion, a PE ratio of -33.58 and a beta of 1.37. The business’s 50-day simple moving average is $55.61 and its 200-day simple moving average is $51.15.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.09. Tabula Rasa HealthCare had a negative return on equity of 1.51% and a negative net margin of 11.39%. The firm had revenue of $73.22 million for the quarter, compared to analyst estimates of $72.67 million. During the same period in the previous year, the company posted $0.21 earnings per share. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. Research analysts forecast that Tabula Rasa HealthCare Inc will post -0.15 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of TRHC. California Public Employees Retirement System increased its stake in Tabula Rasa HealthCare by 283.5% during the third quarter. California Public Employees Retirement System now owns 32,600 shares of the company’s stock valued at $1,791,000 after acquiring an additional 24,100 shares during the period. State Street Corp increased its stake in Tabula Rasa HealthCare by 2.7% during the third quarter. State Street Corp now owns 546,513 shares of the company’s stock valued at $30,025,000 after acquiring an additional 14,504 shares during the period. California State Teachers Retirement System increased its stake in Tabula Rasa HealthCare by 1.2% during the third quarter. California State Teachers Retirement System now owns 30,396 shares of the company’s stock valued at $1,670,000 after acquiring an additional 363 shares during the period. Point72 Asset Management L.P. increased its stake in Tabula Rasa HealthCare by 892.4% during the third quarter. Point72 Asset Management L.P. now owns 188,231 shares of the company’s stock valued at $10,341,000 after acquiring an additional 169,263 shares during the period. Finally, Squarepoint Ops LLC increased its stake in Tabula Rasa HealthCare by 124.4% during the third quarter. Squarepoint Ops LLC now owns 53,407 shares of the company’s stock valued at $2,934,000 after acquiring an additional 29,609 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.

A number of equities analysts have recently commented on the company. William Blair reiterated an “outperform” rating on shares of Tabula Rasa HealthCare in a research note on Friday, January 17th. Oppenheimer assumed coverage on Tabula Rasa HealthCare in a research note on Friday, February 14th. They issued a “buy” rating and a $78.00 price objective on the stock. Wells Fargo & Co reiterated a “hold” rating on shares of Tabula Rasa HealthCare in a research note on Friday, February 28th. ValuEngine lowered Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 18th. Finally, BidaskClub upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $65.88.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Read More: Closed-End Mutual Funds (CEFs)

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.